e-med-isral-ribbon

פסיכיאטריה

Study Suggests New Formulation of Paroxetine May Help Patients Adhere to Their Medication

CHAPEL HILL, NC — July 17, 2002 —

Controlled-release paroxetine, known as Paxil CR, may increase treatment compliance for patients with depression, according to a study published in the July issue of the Journal of Clinical Psychiatry.

This study demonstrated that controlled-release paroxetine is well tolerated with low patient dropout rates. Controlled-release paroxetine patients also reported low rates of nausea at week one, a common reason for stopping antidepressants early in the course of treatment. Research shows that more than half of patients taking antidepressants stop within the first three months because of adverse events.

 This is significant because expert guidelines recommend that patients take antidepressants for six months or longer to prevent relapse. “Patients stand a much greater chance of alleviating their depression if they complete a full course of antidepressant therapy,” said Robert N. Golden, M.D., lead investigator and professor and chair, Department of Psychiatry, University of North Carolina School of Medicine.

 “Unfortunately, patients often stop prematurely because they can’t tolerate the side effects associated with the medication. This study demonstrates that patients taking controlled-release paroxetine were able to tolerate the medication, with a low frequency of patient drop outs due to adverse events, which ultimately may help patients adhere to treatment.”

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ אי-מד שיווק רפואי בע”מ
 כל הזכויות שמורות
09-765-8233 

 

הנך גולש/ת באתר כאורח/ת.

במידה והנך מנוי את/ה מוזמן/ת לבצע כניסה מזוהה וליהנות מגישה לכל התכנים המיועדים למנויים
עדיין לא מנוי/ה ונמנה/ת על הצוות הרפואי? מוזמן/ת לבצע הרשמה כאן
להרשמה לאתר
להמשך גלישה כאורח סגור חלון זה